Improving cognitive function with intermittent dose escalation of curcumin extract in chemotherapy-induced cognitive impairment patients: a randomized controlled trial

Abstract

Chemotherapy-induced cognitive impairment (CICI) is an impairment of memory, learning power, concentration, reasoning, executive function, attention, and visuospatial during and after chemotherapy exposures. No proven safe and effective therapeutic regimen are available to improve cognitive function in CICI patients. To evaluate the safety and effectiveness of curcumin extract to improve cognitive function in CICI patients. This study was a double-blind randomized controlled trial clinical trial in patients with cervical carcinoma who underwent a carboplatin-paclitaxel chemotherapy regimen from March to October 2021 at single center hospital. Subjects divided into two groups that received curcumin and placebo caplets by dose escalation method from 240 to 400 mg intermittently (14 days on and 7 days off) between chemotherapy cycles. Cognitive function was evaluated pre- and post-therapy using the AFI questionnaire, Stroop test, and MoCA-Ina. A total of 78 subjects were equally divided into the treatment and control groups. The percentage of drop-out, mortality, and adverse drug response were relatively comparable between each treatment arm. The group of subjects receiving curcumin extract experienced clinically and statistically significant improvements in cognitive function based on the Stroop test (∆ median 8.57 vs. 2.46; Z − 4.503 vs. − 1.762; p  < 0.0001 vs. 0.078) and MoCA- Ina (∆ mean 1.53 vs. 0.72; Z − 2.99 vs. − 2.05; p < 0.003 vs. 0.04) versus placebo in between-group and between-subject analyses, respectively. Administration of curcumin extract with intermittent dose escalation regimen proved to be safe and able to improve cognitive function of CICI patients clinically and statistically significant.